1) Prodrug linker development for chemotherapy and improving ADC selectivity
2) Biomolecular prodrug development for cancer resistance
3) Development of new prodrug therapies for infectious diseases
4) Synthesis and target ID of natural product analogs with high selectivity toward cancer